

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



開拓藥業有限公司*

KINTOR PHARMACEUTICAL LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 9939)

**VOLUNTARY ANNOUNCEMENT
FIRST BATCH SUBJECTS DOSING IN PHASE I CLINICAL TRIAL OF
GT20029 (AR-PROTAC) IN CHINA**

This is a voluntary announcement made by Kintor Pharmaceutical Limited (the “**Company**”, and together with its subsidiaries, the “**Group**”) to inform the shareholders and potential investors of the Company about the latest business advancement of the Group. Reference is made to the announcements of the Company dated April 15, 2021 and July 13, 2021.

The board of directors (the “**Director(s)**”) of the Company (the “**Board**”) is pleased to announce that the first batch of subjects have been enrolled and dosed in the phase I clinical trial of GT20029 in China (the “**Clinical Trial**”).

The Clinical Trial is a randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics (PK) of GT20029 (gel/tincture) following topical single and multiple ascending dose administration in healthy subjects.

GT20029 is a topical androgen receptor (“**AR**”) compound developed by using the Group’s in-house Proteolysis Targeting Chimera (“**PROTAC**”) platform. To the best of the Directors’ knowledge, GT20029 is the first topical PROTAC compound globally to enter the clinical stage. As an innovative drug for topical use, GT20029 has been shown to avoid systemic exposure. The Center for Drug Evaluation (CDE) of the National Medical Products Administration of China (NMPA) and the U.S. Food and Drug Administration (FDA) approved GT20029’s phase I clinical trial for treating androgenetic alopecia (AGA) and acne vulgaris subjects in China in April 2021 and July 2021 separately.

Warning under Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that GT20029 will ultimately be successfully developed and marketed by the Company. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
KINTOR PHARMACEUTICAL LIMITED
Dr. Youzhi Tong

Chairman of the Board, Executive Director and Chief Executive Officer

Hong Kong, July 28, 2021

As of the date of this announcement, the executive Director is Dr. Youzhi Tong; the non-executive Directors are Mr. Gang Lu, Mr. Weipeng Gao, Dr. Yan Wang, Mr. Wei Zhang and Ms. Yaling Wu; and the independent non-executive Directors are Dr. Michael Min Xu, Mr. Wallace Wai Yim Yeung and Prof. Liang Tong.

* *For identification purpose only*